De Vita V - Search Results

1

Editorial: Autoinflammatory Keratinization Disease (AiKD).

Akiyama M, De Vita V, Sugiura K. Akiyama M, et al. Among authors: de vita v. Front Immunol. 2020 Aug 5;11:1753. doi: 10.3389/fimmu.2020.01753. eCollection 2020. Front Immunol. 2020. PMID: 32849625 Free PMC article. No abstract available.

2

Hidradenitis suppurativa as an autoinflammatory keratinization disease.

De Vita V, McGonagle D. De Vita V, et al. J Allergy Clin Immunol. 2018 May;141(5):1953. doi: 10.1016/j.jaci.2018.01.010. Epub 2018 Mar 2. J Allergy Clin Immunol. 2018. PMID: 29501350 No abstract available.

3

Efficacy and Safety of Microneedling for the Treatment of Cutaneous Warts.

De Vita V, Goldust M. De Vita V, et al. Hand (N Y). 2019 Sep;14(5):705-706. doi: 10.1177/1558944718810895. Epub 2018 Nov 8. Hand (N Y). 2019. PMID: 30406683 Free PMC article. No abstract available.

4

The immunological disease continuum of inflammation against self as an explanation for the lack of association between hidradenitis suppurativa and autoimmune thyroid disease.

De Vita V, McGonagle D. De Vita V, et al. Clin Exp Dermatol. 2018 Jul;43(5):601-603. doi: 10.1111/ced.13374. Epub 2018 Jan 12. Clin Exp Dermatol. 2018. PMID: 29327479 No abstract available.

5

Family physicians' role in hidradenitis suppurativa management.

De Vita V. De Vita V. Can Fam Physician. 2017 May;63(5):352-353. Can Fam Physician. 2017. PMID: 28500191 Free PMC article. No abstract available.

6

Comment on: "Assessing Pruritus in Hidradenitis Suppurativa: A Cross-Sectional Study".

De Vita V, Matusiak Ł, Szepietowski JC. De Vita V, et al. Am J Clin Dermatol. 2017 Oct;18(5):707-708. doi: 10.1007/s40257-017-0314-9. Am J Clin Dermatol. 2017. PMID: 28755065 No abstract available.

7

Altered mTORC1 signalling may contribute to macrophage dysregulation in hidradenitis suppurativa.

De Vita V. De Vita V. Inflamm Res. 2018 Mar;67(3):207-208. doi: 10.1007/s00011-017-1115-6. Epub 2017 Nov 11. Inflamm Res. 2018. PMID: 29127444 No abstract available.

8

Interleukin-32 may contribute to increased risk of cardiovascular disease in patients with hidradenitis suppurativa.

De Vita V, Hansen PR. De Vita V, et al. Atherosclerosis. 2017 Dec;267:175. doi: 10.1016/j.atherosclerosis.2017.10.001. Epub 2017 Oct 7. Atherosclerosis. 2017. PMID: 29037425 No abstract available.

9

Activated mTORC1 signaling: The common driving force of type 2 diabetes and hidradenitis suppurativa.

De Vita V, Melnik BC. De Vita V, et al. J Am Acad Dermatol. 2018 May;78(5):e121. doi: 10.1016/j.jaad.2017.11.061. J Am Acad Dermatol. 2018. PMID: 29678383 No abstract available.

10

Letter to the Editor referring to Hessam et al. - Squamous cell carcinoma arising in hidradenitis suppurativa: subclinical lymphedema may have favored the tumor onset.

De Vita V, Ruocco E. De Vita V, et al. J Dtsch Dermatol Ges. 2017 May;15(5):580-582. doi: 10.1111/ddg.13224. J Dtsch Dermatol Ges. 2017. PMID: 28485866 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

405 results

Search Page

Filters